Structure-Function of UDP-Glucuronosyltransferases
Structure-Function of UDP-Glucuronosyltransferases
批准号:
7272711
负责人:
Anna Radominska-Pandya
金额:
$26.35万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-06-01 至 2010-07-31
关键词:
5-azido-UDP-glucuronic acidActive SitesAffectAmino Acid MotifsAmino AcidsBase SequenceBindingBinding ProteinsBinding SitesC-terminalCarcinogensCatalysisCategoriesChemical StructureChemicalsClassConditionDigestionDiseaseDrug CompoundingDrug InteractionsElementsEnzymesEvaluationFamilyGlucuronosyltransferaseGoalsHumanIndividualIonsKineticsLabelLigandsLocalizedMalignant NeoplasmsMass Spectrum AnalysisMembraneMetabolicMetabolic BiotransformationMetalsMolecularN-terminalNuclear ReceptorsNumbersPharmaceutical PreparationsPharmacogeneticsPharmacotherapyPhasePhotoaffinity LabelsPhysiologicalPoisonProtein IsoformsProteinsProtocols documentationRecombinant ProteinsRecombinantsRegulationResearch PersonnelResourcesRiskRoleSignaling MoleculeSiteSite-Directed MutagenesisSpecificityStructural ProteinStructureStructure-Activity RelationshipSubstrate SpecificityTestingToxic Environmental SubstancesUDP-Glucuronosyltransferase 1A1UGT1A1 geneUridine Diphosphate Glucuronic Acidbasecofactorcomputerizeddesignenvironmental chemicalinhibitor/antagonistinsightmRNA Expressionmolecular modelingmutantpolypeptideresearch studysugar nucleotide
中文摘要
描述(由申请人提供):ugt具有特殊的生理、药理学和毒理学意义,因为它们参与了任何II期代谢酶的最大数量的不同化学结构和来源的内源性化合物、药物和环境毒素的生物转化。此外,一些UGT底物,如核受体配体、信号分子、重要药物和环境化学物质,可以影响UGT mRNA的表达并改变UGT酶的活性。对于作为ugt底物和诱导剂的化学物质的药物遗传学和药物相互作用的理解是一个巨大的需求。由于缺乏用于结构研究的同质蛋白,以前不可能预测葡萄糖醛酸化的分子机制,这是了解UGT底物特异性、抑制作用和药物-药物相互作用的机制方面所必需的。现在已经产生了均匀的UGT蛋白,提出了确定UGT活性位点的研究。我们的中心假设是,UGT的n端结构域由不同的底物识别序列(SRSs)组成,这些序列显示出UGT底物的特异性,从而决定了单个UGT同种异构体的催化机制和底物特异性。对于共底物活性位点,我们假设UDP/Mg2+结合位点位于UGT分子高度保守的c端。具体来说,我们假设DxxD基序在所有ugt中都是保守的。是UDP-GlcUA(共底物)结合位点的主要元素。这些假设将通过以下具体目标进行检验:1。鉴定和表征ugt的底物识别序列。2. 鉴定ugt的UDP-GlcUA结合位点。3. 用质谱法测定光标记多肽的序列。4. 通过位点定向诱变修饰推定结合位点的氨基酸基序,并催化表征所产生的突变体。从这些研究中获得的信息将有助于深入了解葡萄糖醛酸化的分子机制,并将增强我们预测和指导UGTs内源性和外源性底物代谢转化的能力。这些信息对于了解内源性底物和药物之间的特定相互作用将是重要的。它还将作为寻找新的药物和特定UGT同种异构体抑制剂的基础,从而影响药物治疗、药物-药物相互作用以及化学诱发疾病(包括癌症)的风险。
英文摘要
DESCRIPTION (provided by applicant): UGTs are of particular physiological, pharmacological, and toxicological significance due to their involvement in biotransformation of the largest number of endogenous compounds, drugs, and environmental toxins of different chemical structures and origins of any phase II metabolizing enzyme. Moreover, some UGT substrates, which are nuclear receptor ligands, signaling molecules, important drugs, and environmental chemicals, can affect UGT mRNA expression and alter the activity of the UGT enzymes. There is a tremendous need for the understanding of the pharmacogenetics and drug interactions of chemicals that are substrates for and inducers of UGTs. Due to the lack of homogeneous proteins for structural studies, it was previously impossible to predict the molecular mechanism of glucuronidation required to understand the mechanistic aspects of UGT substrate specificity, inhibition, and drug-drug interactions. Now that homogeneous UGT proteins have been generated, studies identifying UGT active sites are proposed. Our central hypothesis is that the N-terminal domain of UGTs consists of distinct substrate recognition sequences (SRSs) that display specificity for classes of UGT substrates and, thus, determine the catalytic mechanism and substrate specificity of individual UGT isoforms. For the co- substrate active site, we hypothesize that the site of UDP/Mg2+ binding is localized in the highly conserved C-terminal end of the UGT molecule. Specifically, we postulate that a DxxD motif, conserved in all UGTs. is a major element of the UDP-GlcUA (co-substrate) binding site. These hypotheses will be tested by the following Specific Aims: 1. To identify and characterize the substrate recognition sequences of UGTs. 2. To identify and characterize the UDP-GlcUA binding site of UGTs. 3. To sequence photolabeled polypeptides by mass spectrometry. 4. To modify amino acid motifs of putative binding sites by site-directed mutagenesis and catalytically characterize the generated mutants. The information derived from the proposed studies will provide insight into the molecular mechanism of glucuronidation and will enhance our ability to predict and direct the metabolic transformation of both endogenous and exogenous substrates for UGTs. This information will be important for understanding specific interactions between endogenous substrates and drugs. It will also serve as a basis in the search for new drugs and inhibitors of specific UGT isoforms, thus affecting drug therapy, drug-drug interactions, and the risk of chemically-induced diseases, including cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6940862
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6645333
-
项目类别:
-
资助金额:$27.51万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6947572
-
项目类别:
-
资助金额:$5.35万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6947533
-
项目类别:
-
资助金额:$5.23万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6479759
-
项目类别:
-
资助金额:$33.9万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6787636
-
项目类别:
-
资助金额:$27.51万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
HUMAN HEPATIC & INTESTINAL UDP GLUCURONOSYLTRANSFERASES
-
批准号:6381608
-
项目类别:
-
资助金额:$24.79万
-
财政年份:1999
-
负责人:Anna Radominska-Pandya
-
依托单位:
HUMAN HEPATIC & INTESTINAL UDP GLUCURONOSYLTRANSFERASES
-
批准号:6177931
-
项目类别:
-
资助金额:$26.58万
-
财政年份:1999
-
负责人:Anna Radominska-Pandya
-
依托单位:
HUMAN HEPATIC & INTESTINAL UDP GLUCURONOSYLTRANSFERASES
-
批准号:2893266
-
项目类别:
-
资助金额:$23.05万
-
财政年份:1999
-
负责人:Anna Radominska-Pandya
-
依托单位:
HUMAN HEPATIC & INTESTINAL UDP GLUCURONOSYLTRANSFERASES
-
批准号:6524487
-
项目类别:
-
资助金额:$25.02万
-
财政年份:1999
-
负责人:Anna Radominska-Pandya
-
依托单位:
RETINOID UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2749611
-
项目类别:
-
资助金额:$21.78万
-
财政年份:1997
-
负责人:Anna Radominska-Pandya
-
依托单位:
RETINOID UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2905938
-
项目类别:
-
资助金额:$22.43万
-
财政年份:1997
-
负责人:Anna Radominska-Pandya
-
依托单位:
RETINOID UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2402833
-
项目类别:
-
资助金额:$21.14万
-
财政年份:1997
-
负责人:Anna Radominska-Pandya
-
依托单位:
RETINOID UDP-GLUCURONOSYLTRANSFERASES
-
批准号:6177658
-
项目类别:
-
资助金额:$23.11万
-
财政年份:1997
-
负责人:Anna Radominska-Pandya
-
依托单位:
STRUCTURE-FUNCTION OF HUMAN UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2150600
-
项目类别:
-
资助金额:$18.11万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
STRUCTURE-FUNCTION OF HUMAN UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2414898
-
项目类别:
-
资助金额:$18.93万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
Structure-Function of UDP-Glucuronosyltransferases
-
批准号:7143067
-
项目类别:
-
资助金额:$28.4万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
STRUCTURE-FUNCTION OF HUMAN UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2701173
-
项目类别:
-
资助金额:$18.83万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
STRUCTURE-FUNCTION OF HUMAN UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2905742
-
项目类别:
-
资助金额:$19.56万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
Structure-Function of UDP-Glucuronosyltransferases
-
批准号:7666021
-
项目类别:
-
资助金额:$26.19万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
海外基金